Evonik Industries (BRSE:018699457) - Stock Price, News & Analysis

018699457 Stock Overview

Produces specialty chemicals in the Asia-Pacific, Europe, the Middle East, Africa, Central and South America, and North America. More details

018699457 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	1/6
Financial Health	5/6
Dividends	5/6

Rewards

Trading at 60.1% below our estimate of its fair value

Earnings are forecast to grow 33.12% per year

Became profitable this year

Risk Analysis

Shares are highly illiquid

Large one-off items impacting financial results

Dividend of 6.63% is not well covered by earnings

Evonik Industries AG Competitors

EMS-CHEMIE HOLDING

SWX:EMSN

CHF 14.9b

Clariant

SWX:CLN

CHF 3.7b

Givaudan

SWX:GIVN

CHF 35.2b

Sika

SWX:SIKA

CHF 37.6b

Price History & Performance

Summary of all time highs, changes and price drops for Evonik Industries
Historical stock prices
Current Share Price	€35.89
52 Week High	€0
52 Week Low	€0
Beta	1.02
11 Month Change	0%
3 Month Change	0%
1 Year Change	0%
33 Year Change	2.51%
5 Year Change	26.06%
Change since IPO	12.97%

Recent updates

Shareholder Returns

	018699457	CH Chemicals	CH Market
7D	0%	-3.9%	-2.2%
1Y	0%	5.1%	6.2%

Return vs Industry: 018699457 underperformed the Swiss Chemicals industry which returned 4.9% over the past year.

Return vs Market: 018699457 underperformed the Swiss Market which returned 6.1% over the past year.

Price Volatility

Is 018699457's price volatile compared to industry and market?
018699457 volatility
018699457 Average Weekly Movement	n/a
Chemicals Industry Average Movement	2.9%
Market Average Movement	3.3%
10% most volatile stocks in CH Market	6.6%
10% least volatile stocks in CH Market	1.6%

Stable Share Price: 018699457's share price has been volatile over the past 3 months compared to the Swiss market.

Volatility Over Time: Insufficient data to determine 018699457's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1873	32,040	Christian Kullmann	corporate.evonik.com

Evonik Industries AG produces specialty chemicals in the Asia-Pacific, Europe, the Middle East, Africa, Central and South America, and North America. It operates through Specialty Additives, Nutrition & Care, Smart Materials, Performance Materials, and Technology & Infrastructure segments. The Specialty Additives segment provides additives for polyurethane; additives, matting agents, fumed silicas, and specialty resins for paints, coatings, and printing inks; isophorone and epoxy curing agents for coatings, adhesives, and composites; and pour-point depressants, and viscosity index improvers for coatings for oil and other lubricants for construction machinery and automotive sector.

Evonik Industries AG Fundamentals Summary

How do Evonik Industries's earnings and revenue compare to its market cap?
018699457 fundamental statistics
Market cap	CHF 7.68b
Earnings (TTM)	CHF 214.14m
Revenue (TTM)	CHF 14.18b

35.9x

P/E Ratio

0.5x

P/S Ratio

Is 018699457 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
018699457 income statement (TTM)
Revenue	€15.16b
Cost of Revenue	€10.64b
Gross Profit	€4.52b
Other Expenses	€4.29b
Earnings	€229.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Mar 05, 2025

Earnings per share (EPS)	0.49
Gross Margin	29.80%
Net Profit Margin	1.51%
Debt/Equity Ratio	43.2%

How did 018699457 perform over the long term?

See historical performance and comparison

Dividends

6.6%

Current Dividend Yield

237%

Payout Ratio

018699457 Stock Overview

Rewards

Risk Analysis

Evonik Industries AG Competitors

SWX:EMSN

CHF 14.9b

SWX:CLN

CHF 3.7b

SWX:GIVN

CHF 35.2b

SWX:SIKA

CHF 37.6b

Price History & Performance

Recent News & Updates

Evonik Industries AG to Report Q1, 2025 Results on May 12, 2025

Evonik Industries AG to Report Q2, 2025 Results on Aug 01, 2025

Second quarter 2024 earnings released: €0.01 loss per share (vs €0.58 loss in 2Q 2023)

Upcoming dividend of €1.17 per share

First quarter 2024 earnings released: EPS: €0.33 (vs €0.10 in 1Q 2023)

Evonik Industries AG, Annual General Meeting, May 28, 2025

Recent updates

Evonik Industries AG to Report Q1, 2025 Results on May 12, 2025

Evonik Industries AG to Report Q2, 2025 Results on Aug 01, 2025

Second quarter 2024 earnings released: €0.01 loss per share (vs €0.58 loss in 2Q 2023)

Upcoming dividend of €1.17 per share

First quarter 2024 earnings released: EPS: €0.33 (vs €0.10 in 1Q 2023)

Evonik Industries AG, Annual General Meeting, May 28, 2025

Full year 2023 earnings released: €1.00 loss per share (vs €1.16 profit in FY 2022)

International Chemical Investors S.E. agreed to acquire Superabsorbents business of Evonik.

Lanxess Reportedly Seeks to Sell Polyurethane Ops

Third quarter 2023 earnings released: €0.21 loss per share (vs €0.46 profit in 3Q 2022)

Second quarter 2023 earnings released: €0.58 loss per share (vs €0.64 profit in 2Q 2022)

Evonik Industries AG to Report Q1, 2024 Results on May 08, 2024

Evonik Industries AG Revises Financial Guidance for the Full Year 2023

RAG Stiftung Not in Hurry to Cut Evonik Stake

Upcoming dividend of €1.17 per share at 5.9% yield

First quarter 2023 earnings released: EPS: €0.10 (vs €0.67 in 1Q 2022)

Full year 2022 earnings released: EPS: €1.16 (vs €1.61 in FY 2021)

SABO S.p.A. acquired TAA derivatives business from Evonik Industries AG (XTRA:EVK).

Kensing, LLC completed the acquisition of Amphoteric Surfactants and Specialty Esters Manufacturing Operations in Hopewell, Virginia from Evonik Industries AG (XTRA:EVK).

Evonik Industries AG to Report Q2, 2023 Results on Aug 04, 2023

Second quarter 2022 earnings released: EPS: €0.64 (vs €0.48 in 2Q 2021)

Kensing, LLC entered into an agreement to acquire Amphoteric Surfactants and Specialty Esters Manufacturing Operations in Hopewell, Virginia from Evonik Industries AG (XTRA:EVK)

Kensing, LLC entered into an agreement to acquire Amphoteric Surfactants and Specialty Esters Manufacturing Operations in Hopewell, Virginia from Evonik Industries AG (XTRA:EVK)

Evonik Industries AG, Annual General Meeting, May 31, 2023

Upcoming dividend of €1.17 per share

First quarter 2022 earnings released: EPS: €0.67 (vs €0.41 in 1Q 2021)

Evonik Industries AG Provides Earnings Guidance for the Full Year 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Evonik Industries AG to Report Q4, 2022 Results on Mar 02, 2023

Third quarter 2021 earnings released: EPS €0.49 (vs €0.32 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.48 (vs €0.26 in 2Q 2020)

Evonik Industries AG (XTRA:EVK) acquired JeNaCell GmbH.

Orion Engineered Carbons S.A. Settles Dispute with Evonik Industries AG

Upcoming dividend of €1.15 per share

First quarter 2021 earnings released: EPS €0.41 (vs €0.29 in 1Q 2020)

Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam

Full year 2020 earnings released

Revenue beats expectations

Evonik Industries AG to Report Q4, 2020 Results on Mar 04, 2021

New 90-day high: CHF35.00

New 90-day high: CHF31.00

Evonik Industries AG (XTRA:EVK) completed the acquisition of LACTEL Absorbable Polymer Product Line of DURECT Corporation (NasdaqCM:DRRX) for $15 million.

Evonik Industries AG to Report Q2, 2021 Results on Aug 05, 2021

Evonik Industries AG to Report Q3, 2021 Results on Nov 04, 2021

Revenue beats expectations

Third quarter 2020 earnings released: EPS €0.32

Evonik Industries AG (XTRA:EVK) entered into a definitive agreement to acquire Porocel Corporation for $210 million.

First half earnings released

Evonik Industries AG (XTRA:EVK) completed the acquisition of Innovativehealth Group,s.l

United Initiators GmbH completed the acquisition of Hydrogen Peroxide (H2O2) plant of Evonik Industries AG (XTRA:EVK).

Shareholder Returns

Price Volatility

About the Company

Evonik Industries AG Fundamentals Summary

35.9x

0.5x

Earnings & Revenue

Dividends

6.6%